Timing of Trastuzumab Administration in Breast CancerTiming of Trastuzumab Administration in Breast Cancer
In the neoadjuvant treatment of HER2-positive breast cancer, administering trastuzumab concurrently with anthracyclines offers no advantage over sequential administration. Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Health | Hematology | HER2 | Herceptin | Neoadjuvant Therapy